DOT1L and acute myeloid leukemia: Recently, several groups reported that addition of LSD1 inhibitors to other molecular entities could be a promising therapy against AML, such as DNMT inhibitor, pan-HDAC inhibitor, Dot1L inhibitor and ATRA (all trans-retinoid acid) [2, 4, 80, 81].